Edition:
United Kingdom

Alkermes Plc (ALKS.OQ)

ALKS.OQ on NASDAQ Stock Exchange Global Select Market

58.60USD
23 Feb 2018
Change (% chg)

$2.05 (+3.63%)
Prev Close
$56.55
Open
$56.67
Day's High
$58.88
Day's Low
$56.59
Volume
401,154
Avg. Vol
369,396
52-wk High
$71.22
52-wk Low
$46.65

Select another date:

Wed, Feb 14 2018

BRIEF-Alkermes PLC Reports Q4 Non-Gaap Earnings Per Share $0.31

* REPORTS FINANCIAL RESULTS FOR THE YEAR ENDED DEC. 31, 2017 AND PROVIDES FINANCIAL EXPECTATIONS FOR 2018

BRIEF-Alkermes Submits NDA To U.S. FDA For ALKS 5461 FOR ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER

* ALKERMES SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR ALKS 5461 FOR THE ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER Source text for Eikon: Further company coverage:

BRIEF-Primecap Management Co Reports A 11.35 Pct Passive Stake In Alkermes

* PRIMECAP MANAGEMENT CO REPORTS A 11.35 PCT PASSIVE STAKE IN ALKERMES PLC AS OF NOV 30 - SEC FILING Source text: (http://bit.ly/2A7WmiG) Further company coverage:

Biogen boosts multiple sclerosis holding with Alkermes license

Biogen Inc said on Monday it has licensed Alkermes Plc's multiple sclerosis (MS) drug, further boosting its position in the race for the next treatment amid slowing sales of its own flagship MS drug, Tecfidera.

Biogen boosts multiple sclerosis holding with Alkermes license

Nov 27 Biogen Inc said on Monday it has licensed Alkermes Plc's multiple sclerosis (MS) drug, further boosting its position in the race for the next treatment amid slowing sales of its own flagship MS drug, Tecfidera.

BRIEF-Alkermes Expects 2017 Non-GAAP Income Of $0.03 To $0.22/Shr

* ALKERMES PLC- NOW EXPECTS 2017 TOTAL REVENUES TO RANGE FROM $870 MILLION TO $900 MILLION‍​ - SEC FILING

BRIEF-Alkermes’ NDA for ARISTADA accepted for filing by U.S. FDA

* Alkermes’ New Drug Application for Investigational Product Designed for Initiation Onto ARISTADA® accepted for filing by U.S. FDA

BRIEF-ALKERMES INITIATES CLINICAL STUDY EVALUATING ARISTADA, INVEGA SUSTENNA FOR SCHIZOPHRENIA

* ALKERMES TO INITIATE NEW CLINICAL STUDY EVALUATING ARISTADA® AND INVEGA SUSTENNA® FOR THE TREATMENT OF SCHIZOPHRENIA

BRIEF-ALKERMES PLC REPORTS ‍Q3 GAAP LOSS PER SHARE OF $0.24

* ‍Q3 TOTAL REVENUES INCREASED 21% YEAR-OVER-YEAR TO $217.4 MILLION​

Select another date: